questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Agents hématologiques
Anticoagulants
Antithrombiniques
Antithrombiniques : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Thrombose
Échographie
D-dimères
Anticoagulants
Temps de prothrombine
INR
Embolie
Douleur thoracique
Essoufflement
Insuffisance veineuse
Doppler
Examen physique
Thrombose veineuse
Œdème
Douleur
Symptômes
5
Thrombose
Douleur
Gonflement
Embolie pulmonaire
Tachycardie
Essoufflement
Hémorragie
Saignement
Ecchymoses
Thrombopénie
Saignements
Pétéchies
Thromboembolie
Cyanose
Douleur
Prévention
5
Thrombose
Prévention
Exercice
Anticoagulants
Risque
Voyages
Bas de compression
Circulation
Thrombose
Alimentation
Vitamine K
Anticoagulants
Facteurs de risque
Poids
Tabac
Traitements
5
Antithrombiniques
Héparine
Warfarine
Héparine
Injection
Anticoagulants
Anticoagulants
Effets secondaires
Saignements
Anticoagulants
INR
Temps de prothrombine
Thrombose veineuse
Anticoagulants
Compression
Complications
5
Anticoagulants
Hémorragies
Thrombopénie
Surdose
Anticoagulants
Saignements
Hémorragie
Anticoagulants
Consultation médicale
Thrombose
Embolie pulmonaire
Syndrome post-thrombotique
Anticoagulants
Saignements
Coagulation
Facteurs de risque
5
Thrombose
Obésité
Antécédents familiaux
Âge
Thrombose
Circulation sanguine
Tabagisme
Thrombose
Inflammation
Maladies chroniques
Diabète
Hypertension
Grossesse
Thrombose
Changements hormonaux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antithrombiniques : Questions médicales les plus fréquentes",
"headline": "Antithrombiniques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antithrombiniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antithrombiniques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Anticoagulants",
"url": "https://questionsmedicales.fr/mesh/D000925",
"about": {
"@type": "MedicalCondition",
"name": "Anticoagulants",
"code": {
"@type": "MedicalCode",
"code": "D000925",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.502.119"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du facteur Xa",
"alternateName": "Factor Xa Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065427",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du facteur Xa",
"code": {
"@type": "MedicalCode",
"code": "D065427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.502.119.500.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antithrombiniques",
"alternateName": "Antithrombins",
"code": {
"@type": "MedicalCode",
"code": "D000991",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Vicente Vicente",
"url": "https://questionsmedicales.fr/author/Vicente%20Vicente",
"affiliation": {
"@type": "Organization",
"name": "Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain."
}
},
{
"@type": "Person",
"name": "Javier Corral",
"url": "https://questionsmedicales.fr/author/Javier%20Corral",
"affiliation": {
"@type": "Organization",
"name": "Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain."
}
},
{
"@type": "Person",
"name": "Irene Martínez-Martínez",
"url": "https://questionsmedicales.fr/author/Irene%20Mart%C3%ADnez-Mart%C3%ADnez",
"affiliation": {
"@type": "Organization",
"name": "Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain. Electronic address: immlgi@um.es."
}
},
{
"@type": "Person",
"name": "Belén de la Morena-Barrio",
"url": "https://questionsmedicales.fr/author/Bel%C3%A9n%20de%20la%20Morena-Barrio",
"affiliation": {
"@type": "Organization",
"name": "Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain."
}
},
{
"@type": "Person",
"name": "Zsuzsanna Bereczky",
"url": "https://questionsmedicales.fr/author/Zsuzsanna%20Bereczky",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Transition of Care to Adult Neuroimmunology.",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37451748",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.spen.2023.101052"
}
},
{
"@type": "ScholarlyArticle",
"name": "Transition to adult care in epilepsy: A systematic review.",
"datePublished": "2022-07-11",
"url": "https://questionsmedicales.fr/article/35901664",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.seizure.2022.07.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of transition readiness to predict health care utilization during transition to adult care in sickle cell disease.",
"datePublished": "2022-11-15",
"url": "https://questionsmedicales.fr/article/36356169",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/17474086.2022.2144216"
}
},
{
"@type": "ScholarlyArticle",
"name": "[The transition of children with rare diseases from pediatric to adult care].",
"datePublished": "2022-12-18",
"url": "https://questionsmedicales.fr/article/36528825",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/650.2022.32660"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Transition of long-term ventilated children to adult medical care].",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37295444",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-2081-0904"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents hématologiques",
"item": "https://questionsmedicales.fr/mesh/D006401"
},
{
"@type": "ListItem",
"position": 6,
"name": "Anticoagulants",
"item": "https://questionsmedicales.fr/mesh/D000925"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antithrombiniques",
"item": "https://questionsmedicales.fr/mesh/D000991"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antithrombiniques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antithrombiniques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antithrombiniques",
"description": "Comment diagnostiquer une thrombose ?\nQuels tests pour évaluer l'anticoagulation ?\nQuels symptômes indiquent une embolie ?\nComment détecter une insuffisance veineuse ?\nQuels signes cliniques d'une thrombose veineuse ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antithrombiniques",
"description": "Quels sont les symptômes d'une thrombose ?\nComment reconnaître une embolie pulmonaire ?\nQuels symptômes d'une hémorragie ?\nQuels signes d'une thrombopénie ?\nComment se manifeste une crise thromboembolique ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antithrombiniques",
"description": "Comment prévenir les thromboses ?\nQuels conseils pour les patients à risque ?\nComment utiliser les bas de compression ?\nQuels aliments éviter pour prévenir les caillots ?\nComment gérer les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antithrombiniques",
"description": "Quels médicaments sont des antithrombiniques ?\nComment administrer l'héparine ?\nQuels sont les effets secondaires des anticoagulants ?\nComment surveiller l'efficacité des anticoagulants ?\nQuels traitements pour la thrombose veineuse ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antithrombiniques",
"description": "Quelles sont les complications des anticoagulants ?\nQuels risques d'une surdose d'anticoagulants ?\nComment gérer une hémorragie sous anticoagulants ?\nQuelles sont les complications de la thrombose ?\nQuels effets à long terme des anticoagulants ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antithrombiniques",
"description": "Quels sont les facteurs de risque de thrombose ?\nComment l'âge influence-t-il le risque ?\nQuel rôle joue le tabagisme ?\nComment les maladies chroniques affectent-elles le risque ?\nQuel impact a la grossesse sur le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000991?mesh_terms=Transition+to+Adult+Care#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une thrombose ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic de thrombose se fait par échographie, D-dimères et examens cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'anticoagulation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le temps de prothrombine (TP) et l'INR pour surveiller l'anticoagulation."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une embolie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur thoracique, essoufflement et toux avec sang."
}
},
{
"@type": "Question",
"name": "Comment détecter une insuffisance veineuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'insuffisance veineuse se détecte par examen physique et Doppler veineux."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques d'une thrombose veineuse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent œdème, rougeur, chaleur et douleur au niveau de la jambe."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une thrombose ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, gonflement, rougeur et chaleur dans la zone affectée."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une embolie pulmonaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent douleur thoracique aiguë, essoufflement et tachycardie."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une hémorragie ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent saignements inhabituels, ecchymoses et fatigue excessive."
}
},
{
"@type": "Question",
"name": "Quels signes d'une thrombopénie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements fréquents, des ecchymoses et des pétéchies."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une crise thromboembolique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par une douleur soudaine, un essoufflement et une cyanose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les thromboses ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'exercice régulier, l'hydratation et l'évitement de la sédentarité."
}
},
{
"@type": "Question",
"name": "Quels conseils pour les patients à risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent suivre un traitement anticoagulant et éviter les voyages longs."
}
},
{
"@type": "Question",
"name": "Comment utiliser les bas de compression ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bas de compression aident à améliorer la circulation et à réduire le risque de thrombose."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter pour prévenir les caillots ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les aliments riches en vitamine K comme les légumes à feuilles vertes si sous anticoagulants."
}
},
{
"@type": "Question",
"name": "Comment gérer les facteurs de risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Gérer les facteurs de risque inclut le contrôle du poids, l'arrêt du tabac et le traitement des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des antithrombiniques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antithrombiniques incluent l'héparine, la warfarine et les nouveaux anticoagulants."
}
},
{
"@type": "Question",
"name": "Comment administrer l'héparine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'héparine est administrée par injection sous-cutanée ou intraveineuse selon les besoins."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des anticoagulants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent saignements, ecchymoses et réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité des anticoagulants ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité se surveille par des tests sanguins réguliers comme l'INR et le temps de prothrombine."
}
},
{
"@type": "Question",
"name": "Quels traitements pour la thrombose veineuse ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent anticoagulants, compression et parfois intervention chirurgicale."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications des anticoagulants ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent hémorragies, thrombopénie et interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quels risques d'une surdose d'anticoagulants ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des saignements graves et nécessite une attention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Comment gérer une hémorragie sous anticoagulants ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas d'hémorragie, il faut arrêter l'anticoagulant et consulter un médecin rapidement."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la thrombose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'embolie pulmonaire, le syndrome post-thrombotique et la douleur chronique."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme des anticoagulants ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des saignements récurrents et des problèmes de coagulation."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de thrombose ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, l'immobilité, les antécédents familiaux et certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque de thrombose augmente avec l'âge en raison de la diminution de la circulation sanguine."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le tabagisme ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme augmente le risque de thrombose en favorisant l'inflammation et la coagulation."
}
},
{
"@type": "Question",
"name": "Comment les maladies chroniques affectent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies chroniques comme le diabète et l'hypertension augmentent le risque de thrombose."
}
},
{
"@type": "Question",
"name": "Quel impact a la grossesse sur le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La grossesse augmente le risque de thrombose en raison des changements hormonaux et circulatoires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
9 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
8 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain.
5 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain. Electronic address: immlgi@um.es.
Publications dans "Antithrombiniques" :
4 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain.
Publications dans "Antithrombiniques" :
4 publications dans cette catégorie
Affiliations :
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Publications dans "Antithrombiniques" :
4 publications dans cette catégorie
Affiliations :
Hematology and Medical Oncology Unit, Morales Meseguer University Hospital, Regional Blood Donation Center, University of Murcia, Biomedical Research Institute of Murcia (IMIB), CIBER Rare Diseases (CIBERER), Murcia, Spain
Publications dans "Antithrombiniques" :
4 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Department of Hematology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Publications dans "Antithrombiniques" :
3 publications dans cette catégorie
Affiliations :
Department of Hematology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, U-765, Center for Biomedical Research on Rare Diseases, Murcia, Spain.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia, Spain.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Publications dans "Antithrombiniques" :
2 publications dans cette catégorie
Affiliations :
Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Publications dans "Antithrombiniques" :
A structured health care transition is essential for adolescents with chronic disease to ensure continuity of care without treatment lapse. Though rare, multiple sclerosis is diagnosed in children and...
The transfer from paediatric to adult care can be a complex process in children with epilepsy. Inadequate care during this phase can affect long-term medical and psychosocial outcomes. The aim of this...
Transition-age patients with sickle cell disease (SCD) are at risk for poor outcomes associated with incomplete transition readiness and neurocognitive deficits. Study objectives were to: 1) test if a...
Youth/caregivers were selected from a longitudinal cohort study. Caregivers completed the Behavior Rating Inventory of Executive Function (BRIEF); caregivers and youth completed the Self-Management Sk...
In total, 95 participants (54% male, 55% severe genotype) completed the SMSC assessment. Most participants (87%) transferred to adult care within six months and 87% were retained for at least 12 month...
The SMSC and executive function did not predict adult care engagement. Development of readiness assessments that predict care engagement and reflect self-efficacy is important for monitoring transitio...
Diagnostics for rare diseases have advanced as a result of technological advancement. Innovative treatments have also made it possible for children with rare disorders to survive into adulthood. Growi...
Through advances in long-term ventilation, the number of children with chronic respiratory insufficiency reaching adult age has increased tremendously. Therefore, transition of children from pediatric...
In Belgium, there is not yet a standardized procedure for supporting the transition of patients with chronic diseases from pediatrics to adult health care. However, the field increasingly calls for th...
Chronic gastrointestinal disorders are prevalent in youth worldwide. The chronicity of these conditions often results in their persistence into adulthood. Challenges typically faced by young people tr...
With juvenile idiopathic arthritis (JIA), there are several protocols and practices used worldwide for the transition from paediatric to adult care. In this study, we examined the transferral rates an...
The study population comprised 408 participants with a disease onset from 1997 to 2000 who attended an 18-year follow-up visit in this population-based Nordic JIA cohort study. The patients were retro...
One hundred and sixty-three (40%) JIA patients had been directly transferred to an adult clinic. The cumulative transition rate was 52%, but there were significant differences between the participatin...
This study highlights the need to reconsider transition practices to avoid our undesirable finding of patients with disease activity in JIA, but no appropriate health care follow-up....
The aim of this study was to evaluate the experiences of patients aged 18-24 years who were diagnosed with multiple sclerosis before the age of eighteen, during the transition from pediatric care to a...
This research was in the type of phenomenological qualitative research. Focus group interviews were conducted between December 2020 and October 2021 with seventeen participants who had been diagnosed ...
Of the participants, 58.9% were female, 76.5% had their first attack after the age of 13, and it was determined that 64.7% of them took oral tablets for therapeutic purposes. As a result of the conten...
This study revealed that individuals with multiple sclerosis did not receive any medical care regarding the transition from pediatric clinics to adult clinics. Describing the experiences of young adul...
The transition to adult health care (HCT, Health Care Transition), is the purposeful, planned movement of patients from paediatric to adult services. For the adolescent living with obesity (ALwO), the...